Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (12): 1321-1324.
DOI: 10.19803/j.1672-8629.20210621
Previous Articles Next Articles
GAO Qinqin1, LIANG Guodong1, ZHOU Zexuan1, SHENG Wei1, XU Xiaoshuang2, LIU Weidong1,*, NA Heiya3,#
Received:
2021-06-19
Online:
2022-12-15
Published:
2022-12-21
CLC Number:
GAO Qinqin, LIANG Guodong, ZHOU Zexuan, SHENG Wei, XU Xiaoshuang, LIU Weidong, NA Heiya. Acute toxicity and long toxicity of Mongolian medicine sea-buckthorn syrup on 14-day-old SD rats[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1321-1324.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20210621
[1] LIANG GD, ZHAO FR.Situation of Mongolian medicine sea-buckthorn syrup and its modern research and development status[J]. Journal of Medicine & Pharmacy of Chinese Minorities(中国民族医药杂志), 2019, 25(2): 41-44. [2] HU SH. Yinshan Zhengyao (printed version)(饮膳正要)[M]. The seventh year of Jingtai in the Ming Dynasty (1456 A.D.). [3] XU ZL, HOU ZC, LAN TH.Preliminary study on vinegar willow juice[J]. Acta Nutrimenta Sinica(营养学报), 1956, 1(4): 333-350. [4] Department of Health of Inner Mongolia Autonomous Region. Standards for Mongolian Medicine in Inner Mongolia(内蒙古蒙成药标准)[M].1984: 382-383. [5] ZHU HZ.Drug liability and consumer protection[J]. Pharmaceutical Newsweek(医药新闻周刊), 1997, 16(3): 2581-2582. [6] ZHAO ZH, ZHANG L, LI WB, et al.Research progress on safety evaluation and toxicity of traditional chinese medicine[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2018, 24(20): 208-216. [7] ZHANG BL, CHENG YY, QU HB, et al.Innovation, research and industrialization of core technology system for secondary development of Chinese patent medicine[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2015, 32(1): 1-3. [8] LIANG GD, WU QJ, NA HY.Effect of sea-buckthorn syrup on digestion in dyspesia mice model[J]. Journal of Pharmaceutical Research(药学研究), 2020, 39(9): 501-539. [9] LIANG GD, WU QJ, NA HY.Experimental studies on antitussive and expectorant effects of Sea-buckthorn Syrup[J]. Journal of Pharmaceutical Research(药学研究), 2020, 39(10): 562-574. [10] DONG TT, TIAN X, LU P, et al.Comparison and suggestion for implementation of“Technical guidelines for repeated drug administration toxicity testing”and“Technical guidelines for pharmacokinetic research” and ICH S4 and ICH S3A guidelines[J]. Drugs & Clinic(现代药物与临床), 2018,33(10): 2753-2757. [11] SUN ZY, ZHOU L.Strategy of study design to non-clinical safety evaluation of paediatruc medicines[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(21): 2473-2482. [12] CHEN QS, CAI SF, TAN YF, et al.Acute toxicity of mangrove plant lumnitzera racemosa extract on mice[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 72-74,86. [13] GUO Y, HE W, LUO FX, et al.Study the acute toxicity and sub-acute toxicity of apocynum extract in mice by intragastric administration[J]. Xinjiang Medical Journal(新疆医学), 2019, 49(8): 770-773. [14] GAO ZW, ZHANG X, MO ZH, et al.Single dose toxicity of ficus microcarpa in mice[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2022,19(3): 1-10. [15] ZHANG Y.Toxicological Safety Evaluation of Bound Polyphenols of Seabuckthorn Berries[D]. Taiyuan Shanxi University(山西大学), 2020. |
[1] | SUN Qiyue, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Safe doses of Lingyang Ganmao oral liquid for children based on the multi-animal model [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 121-126. |
[2] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
[3] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
[4] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
[5] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[6] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
[7] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
[8] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[9] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
[10] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[11] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[12] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[13] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[14] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
[15] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||